

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 1093)

VOLUNTARY ANNOUNCEMENT

“ESOMEPRAZOLE SODIUM FOR INJECTION” OBTAINS DRUG REGISTRATION APPROVAL

The board of directors (the “**Board**”) of the CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that the “Esomeprazole Sodium for Injection (40 mg)” (the “**Product**”) developed by CSPC Ouyi Pharmaceutical Co., Ltd.* (石藥集團歐意藥業有限公司), a subsidiary of the Company, has obtained drug registration approval granted by the National Medical Products Administration of the People’s Republic of China, and is deemed to have passed the consistency of quality and efficacy evaluation of generic drugs.

Esomeprazole is a proton pump inhibitor that suppresses gastric acid secretion (both basal and stimulated gastric acid secretion) by specific inhibition of the proton pump in the gastric parietal cell. The Product is indicated for (i) gastroesophageal reflux disease as an alternative therapy when oral therapy is not suitable; (ii) low-risk patients with acute bleeding gastric and duodenal ulcers (Forrest Classification IIc-III) when oral therapy is not suitable; (iii) reducing the risk of rebleeding after endoscopic treatment of bleeding gastric and duodenal ulcers in adults; and (iv) prevention of stress-ulcer bleeding in critically ill patients.

The approval of the Product will further enrich the Group’s product portfolio for digestion system diseases.

By order of the Board
CSPC Pharmaceutical Group Limited
Cai Dongchen
Chairman

Hong Kong, 22 April 2022

** for identification purposes only*

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. WANG Qingxi, Mr. CHAK Kin Man and Dr. JIANG Hao as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan and Mr. LAW Cheuk Kin Stephen as independent non-executive directors.